Synthesis and SAR of Novel Re/99mTc-Labeled Benzenesulfonamide Carbonic Anhydrase IX Inhibitors for Molecular Imaging of Tumor Hypoxia

2013 ◽  
Vol 56 (2) ◽  
pp. 510-520 ◽  
Author(s):  
Genliang Lu ◽  
Shawn M. Hillier ◽  
Kevin P. Maresca ◽  
Craig N. Zimmerman ◽  
William C. Eckelman ◽  
...  
Molecules ◽  
2018 ◽  
Vol 24 (1) ◽  
pp. 23 ◽  
Author(s):  
Kuo-Ting Chen ◽  
Kevin Nguyen ◽  
Christian Ieritano ◽  
Feng Gao ◽  
Yann Seimbille

We herein describe a flexible synthesis of a small library of 68Ga-labeled CAIX-targeted molecules via an orthogonal 2-cyanobenzothiazole (CBT)/1,2-aminothiol click reaction. Three novel CBT-functionalized chelators (1–3) were successfully synthesized and labeled with the positron emitter gallium-68. Cross-ligation between the pre-labeled bifunctional chelators (BFCs) and the 1,2-aminothiol-acetazolamide derivatives (8 and 9) yielded six new 68Ga-labeled CAIX ligands with high radiochemical yields. The click reaction conditions were optimized to improve the reaction rate for applications with short half-life radionuclides. Overall, our methodology allows for a simple and efficient radiosynthetic route to produce a variety of 68Ga-labeled imaging agents for tumor hypoxia.


2007 ◽  
Vol 87 (12) ◽  
pp. 1206-1217 ◽  
Author(s):  
Vladimir V Iakovlev ◽  
Melania Pintilie ◽  
Andrew Morrison ◽  
Anthony W Fyles ◽  
Richard P Hill ◽  
...  

2011 ◽  
Vol 71 (9) ◽  
pp. 3364-3376 ◽  
Author(s):  
Yuanmei Lou ◽  
Paul C. McDonald ◽  
Arusha Oloumi ◽  
Stephen Chia ◽  
Christina Ostlund ◽  
...  

2020 ◽  
Vol 21 (19) ◽  
pp. 7146
Author(s):  
Jean Courcier ◽  
Alexandre de la Taille ◽  
Maya Nourieh ◽  
Ingrid Leguerney ◽  
Nathalie Lassau ◽  
...  

Carbonic Anhydrase IX (CAIX) is a well-described enzyme in renal cell carcinoma, with its expression being regulated by the hypoxia-inducible factor 1 alpha, it is known for interfering with hypoxia processes. Renal carcinoma encompasses a broad spectrum of histological entities and is also described as a heterogeneous malignant tumor. Recently, various combinations of checkpoint inhibitors and targeted therapies have been validated to manage this disease. Reliable markers to confirm the diagnosis, estimate the prognosis, predict or monitor the treatment response are required. Molecular imaging developments allow a comprehensive analysis of the tumor, overcoming the spatial heterogeneity issue. CAIX, being highly expressed at the tumor cell surfaces of clear cell renal carcinoma, also represents a potential treatment target. In this manuscript we reviewed the current knowledge from the literature on the pathophysiological interactions between renal cell carcinoma and CAIX, the role of CAIX as a marker for diagnosis, prognosis, treatment monitoring and molecular imaging, and the potential target for therapeutic strategies.


2015 ◽  
Vol 11 (10) ◽  
pp. 1531-1541 ◽  
Author(s):  
Jianbo Li ◽  
Guojian Zhang ◽  
Xuemei Wang ◽  
Xiao-Feng Li

2010 ◽  
Vol 37 (5) ◽  
pp. 557-564 ◽  
Author(s):  
Vamsidhar Akurathi ◽  
Ludwig Dubois ◽  
Natasja G. Lieuwes ◽  
Satish K. Chitneni ◽  
Bernard J. Cleynhens ◽  
...  

Immunotherapy ◽  
2013 ◽  
Vol 5 (5) ◽  
pp. 489-495 ◽  
Author(s):  
Stijn Muselaers ◽  
Peter Mulders ◽  
Egbert Oosterwijk ◽  
Wim Oyen ◽  
Otto Boerman

Sign in / Sign up

Export Citation Format

Share Document